Meeting
2022 ASCO Annual Meeting
Camrelizumab plus apatinib as induction therapy for locally advanced head and neck squamous cell carcinoma (IMplus): A single-arm phase II study.
Authors
Lulu Ye
Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology, Shanghai, China
Lulu Ye , Lin Zhang , Rongrong Li , Shengjin Dou , Wen Jiang , Guopei Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04440917
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6060)
DOI
10.1200/JCO.2022.40.16_suppl.6060
Abstract #
6060
Poster Bd #
52
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.
First Author: Yakun Wang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.
First Author: Feng Wang
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang
Poster
2021 ASCO Annual Meeting
Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).
First Author: Lai-Ping Zhong